Replies to post #213831 on Biotech Values

[Bickema]

As previously noted, Mavyret’s absolute script numbers reported by IMS are low because IMS misses much of the public sector of the HCV market that ABBV is targeting.

1.Does this mean we have to wait until ABBV ER to understand absolute market share?

2.Also, do you have an idea of what the street's consensus is in regards to market share?

3.with ENTA trading at 43-44, what market share is its share price tracking at?

Thank you!

[DewDiligence]

ENTA—Mavyret scripts for week ending 9/22/17 (from IMS)…

TRx: 376, +33% from prior week
NRx: 267, +19% from prior week

We are now 8 weeks into the US launch.

(As previously noted, Mavyret’s absolute script numbers reported by IMS are low because IMS misses much of the public sector of the HCV market that ABBV is targeting.)